PROTEUS Trial at ASCO 2026: Perioperative Apalutamide Plus ADT in high-risk localized or locally advanced prostate cancer

oncodaily - PROTEUS trial, was presented during the ASCO 2026 Plenary Session by Mary-Ellen Taplin, MD, FASCO. The study evaluated one year of perioperative apalutamide plus androgen deprivation therapy in patients with […]

AI Summary: A perioperative strategy adding apalutamide to androgen‑deprivation therapy around radical prostatectomy shows improved outcomes for men with high‑risk or locally advanced prostate cancer, reducing metastasis and disease‑related death. Findings were highlighted and debated at ASCO sessions, prompting discussion about changing perioperative standards — and yes, surgeons are already updating their talking points.

#healthcare #pharmaceuticals #drugdevelopment #oncology #cancerresearch #clinicaltrials

Adding Apalutamide to Perioperative ADT Associated with Better Outcomes of Radical Prostatectomy for High-Risk Localised or Locally Advanced Prostate Cancer

2 hrs / esmo

Declan Murphy: Plenary Discussion on the Wonderful PROTEUS Trial

2 hrs / oncodaily

Perioperative apalutamide in high-risk localized or locally advanced prostate cancer reduces risk of metastasis, death

45 hrs / medicalxpress

Mark Wildgust: It’s ASCO Plenary Day! Excited for a Packed Room to Hear the Results From Proteus!

2 days / oncodaily

PROTEUS Trial at ASCO 2026: Perioperative Apalutamide Plus ADT in high-risk localized or locally advanced prostate cancer

2 days / oncodaily

Blog Post

PROTEUS (Phase III) — presented at the ASCO 2026 Plenary by Mary‑Ellen Taplin, MD — found that adding apalutamide to perioperative androgen‑deprivation therapy (given before and after radical prostatectomy, for about one year) in men with high‑risk localized or locally advanced prostate cancer increased major pathologic responses and reduced the risk of metastasis or disease‑related death, meeting both primary endpoints. The international trial (co‑led by Taplin and Adam Kibel, MD) has prompted plenary‑level discussion about changing perioperative practice — and surgeons are already updating their talking points. Sources: PROTEUS ASCO presentation and coverage (Medical Xpress, ESMO, OncoDaily).

GLP-1 use linked to lower breast cancer incidence in large cohort study

medicalxpress - A retrospective analysis of more than 110,000 women between the ages of 45 and 80 found that those who took GLP-1 medications were about 30% less likely to develop breast cancer than those who did not take GLP-1 medications, according to research presente…

AI Summary: A large observational cohort study reported an association between GLP‑1 agonist use and a lower incidence of breast cancer. The result is intriguing and may spur biological investigation, but researchers caution against causal claims—confounding and indication bias mean randomized trials would be required to confirm any protective effect.

#obesity #pharmaceuticals #weightloss #drugdevelopment #oncology #cancerresearch #clinicaltrials #diabetes

Cancer researchers present advances and emerging treatments

1 hr / medicalxpress

GLP-1 use linked to lower breast cancer risk: Study

18 hrs / beckershospitalreview / Ella Jeffries

GLP-1 use linked to lower breast cancer incidence in large cohort study

21 hrs / medicalxpress

17,000-year-old stripes of red in a Welsh cave are the oldest rock art in the UK, study finds

22 hrs / livescience

StackHealth RSS

You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Price Transparency, Avian Influenza, Novo Nordisk, Research Funding and look for the RSS link.

StackHealth Time Machine

More StackHealth